These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24105953)

  • 1. Macromolecular prodrugs for controlled delivery of ribavirin.
    Kryger MB; Smith AA; Wohl BM; Zelikin AN
    Macromol Biosci; 2014 Feb; 14(2):173-85. PubMed ID: 24105953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Narrow therapeutic window of ribavirin as an inhibitor of nitric oxide synthesis is broadened by macromolecular prodrugs.
    Wohl BM; Smith AA; Kryger MB; Zelikin AN
    Biomacromolecules; 2013 Nov; 14(11):3916-26. PubMed ID: 24156371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation.
    Wohl BM; Smith AA; Jensen BE; Zelikin AN
    J Control Release; 2014 Dec; 196():197-207. PubMed ID: 25451544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macromolecular prodrugs of ribavirin: concerted efforts of the carrier and the drug.
    Smith AA; Wohl BM; Kryger MB; Hedemann N; Guerrero-Sanchez C; Postma A; Zelikin AN
    Adv Healthc Mater; 2014 Sep; 3(9):1404-7. PubMed ID: 24408515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug.
    Kryger MB; Wohl BM; Smith AA; Zelikin AN
    Chem Commun (Camb); 2013 Apr; 49(26):2643-5. PubMed ID: 23431562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects.
    Zuwala K; Riber CF; Løvschall KB; Andersen AHF; Sørensen L; Gajda P; Tolstrup M; Zelikin AN
    J Control Release; 2018 Apr; 275():53-66. PubMed ID: 29432822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes.
    Craparo EF; Triolo D; Pitarresi G; Giammona G; Cavallaro G
    Biomacromolecules; 2013 Jun; 14(6):1838-49. PubMed ID: 23621358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macromolecular Prodrugs of Ribavirin: Structure-Function Correlation as Inhibitors of Influenza Infectivity.
    Riber CF; Hinton TM; Gajda P; Zuwala K; Tolstrup M; Stewart C; Zelikin AN
    Mol Pharm; 2017 Jan; 14(1):234-241. PubMed ID: 28043136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tools of gene transfer applied to the intracellular delivery of non-nucleic acid polyanionic drugs.
    Kryger MB; Pedersen SL; Wohl BM; Zelikin AN
    Chem Commun (Camb); 2016 Jan; 52(5):889-91. PubMed ID: 26576493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel composed galactosylated nanodevices containing a ribavirin prodrug as hepatic cell-targeted carriers for HCV treatment.
    Craparo EF; Teresi G; Licciardi M; Bondí ML; Cavallaro G
    J Biomed Nanotechnol; 2013 Jun; 9(6):1107-22. PubMed ID: 23858977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect.
    Guo H; Sun S; Yang Z; Tang X; Wang Y
    J Control Release; 2015 Jul; 209():27-36. PubMed ID: 25883028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells.
    Ruiz-Sanchis P; Wohl BM; Smith AA; Zuwala K; Melchjorsen J; Tolstrup M; Zelikin AN
    Adv Healthc Mater; 2015 Jan; 4(1):65-8. PubMed ID: 25132665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C.
    Grattagliano I; Russmann S; Palmieri VO; Jüni P; Bihl F; Portincasa P; Palasciano G; Lauterburg BH
    Hepatology; 2004 May; 39(5):1248-55. PubMed ID: 15122753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity.
    Hinton TM; Zuwala K; Deffrasnes C; Todd S; Shi S; Marsh GA; Dearnley M; Wohl BM; Tolstrup M; Zelikin AN
    Adv Healthc Mater; 2016 Mar; 5(5):534-40. PubMed ID: 26789641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
    Vispo E; Labarga P; Guardiola JM; Barreiro P; Miralles C; Rubio R; Miralles P; Aguirrebengoa K; Portu J; Morello J; Rodriguez-Novoa S; Soriano V;
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):419-24. PubMed ID: 20377423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
    Jacobson IM; Brown RS; Freilich B; Afdhal N; Kwo PY; Santoro J; Becker S; Wakil AE; Pound D; Godofsky E; Strauss R; Bernstein D; Flamm S; Pauly MP; Mukhopadhyay P; Griffel LH; Brass CA;
    Hepatology; 2007 Oct; 46(4):971-81. PubMed ID: 17894303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
    Fernández-Rodríguez CM; Morillas RM; Masnou H; Navarro JM; Bárcena R; González JM; Martín-Martín L; Poyato A; Miquel-Planas M; Jorquera F; Casanovas T; Salmerón J; Calleja JL; Solà R; Alonso S; Planas R; Romero-Gomez M
    Gastroenterol Hepatol; 2014 Jan; 37(1):1-8. PubMed ID: 24360571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
    J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
    Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
    Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
    Bacon BR; Shiffman ML; Mendes F; Ghalib R; Hassanein T; Morelli G; Joshi S; Rothstein K; Kwo P; Gitlin N
    Hepatology; 2009 Jun; 49(6):1838-46. PubMed ID: 19291790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.